Immunovant CEO Pete Salzmann retires; Eric Venker appointed; IMVT-1402 adds SjD and CLE indications

Roivant Sciences Ltd.

Pete Salzmann retired as Immunovant CEO and Director; Eric Venker (Roivant President & COO) appointed CEO; Tiago Girao named CFO.
IND cleared for IMVT-1402 in Sjögren’s Disease; registrational study expected summer 2025.
Proof-of-concept study initiated for IMVT-1402 in Cutaneous Lupus Erythematosus (CLE).
Roivant to lead Immunovant investor relations; cash runway supports through Graves' Disease readout in 2027.
Robert Susman and Jacob Bauer join Immunovant Board; George Migausky steps down.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.